Disrupting the Molecular Pathway in Myotonic Dystrophy
Related Experiment Video
Updated: Oct 9, 2025

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
Xiaomeng Xing1, Anjani Kumari1, Jake Brown1
1School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK.
Abstract:
Myotonic dystrophy is the most common muscular dystrophy in adults. It consists of two forms: type 1 (DM1) and type 2 (DM2). DM1 is associated with a trinucleotide repeat expansion mutation, which is transcribed but not translated into protein. The mutant RNA remains in the nucleus, which leads to a series of downstream abnormalities. DM1 is widely considered to be an RNA-based disorder. Thus, we consider three areas of the RNA pathway that may offer targeting opportunities to disrupt the production, stability, and degradation of the mutant RNA.
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Destabilization of Microtubules
ATP Synthase: Mechanism
Cross-bridge Cycle
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...

